COVAD survey 2 long-term outcomes: unmet need and protocol

Zoha Zahid Fazal; Parikshit Sen; Mrudula Joshi; Naveen Ravichandran; James B Lilleker; Vishwesh Agarwal; Sinan Kardes; Minchul Kim; Jessica Day; Ashima Makol; Marcin Milchert; Tamer Gheita; Babur Salim; Tsvetelina Velikova; Abraham Edgar Gracia-Ramos; Ioannis Parodis; Elena Nikiphorou; Ai Lyn Tan; Tulika Chatterjee; Lorenzo Cavagna; Miguel A Saavedra; Samuel Katsuyuki Shinjo; Nelly Ziade; Albert Selva-O'Callaghan; Arvind Nune; Johannes Knitza; Masataka Kuwana; Carlos-Enrique Toro Gutiérrez; Carlo Vinicio Caballero-Uribe; Dzifa Dey; John D Pauling; COVAD Study Group; et al

doi:10.1007/s00296-022-05157-6

COVAD survey 2 long-term outcomes: unmet need and protocol

Zoha Zahid Fazal, Parikshit Sen, Mrudula Joshi, Naveen Ravichandran, James B Lilleker, Vishwesh Agarwal, Sinan Kardes, Minchul Kim, Jessica Day, Ashima Makol, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Elena Nikiphorou, Ai Lyn Tan, Tulika Chatterjee, Lorenzo CavagnaMiguel A Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Albert Selva-O'Callaghan, Arvind Nune, Johannes Knitza, Masataka Kuwana, Carlos-Enrique Toro Gutiérrez, Carlo Vinicio Caballero-Uribe, Dzifa Dey, John D Pauling, COVAD Study Group , et al

Bristol Medical School (THS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

41 Citations (Scopus)

Abstract

Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.

Original language	English
Pages (from-to)	2151-2158
Number of pages	8
Journal	Rheumatology International
Volume	42
Issue number	12
Early online date	14 Aug 2022
DOIs	https://doi.org/10.1007/s00296-022-05157-6
Publication status	Published - 1 Dec 2022

Bibliographical note

Publisher Copyright:
© The Author(s) 2022.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiviral Agents
COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
Humans
Pandemics/prevention & control
Vaccination

Access to Document

10.1007/s00296-022-05157-6Licence: CC BY

Handle.net

Persistent link

Cite this

Fazal, Z. Z., Sen, P., Joshi, M., Ravichandran, N., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Day, J., Makol, A., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., Nikiphorou, E., Tan, A. L., Chatterjee, T., ... al , E. (2022). COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatology International, 42(12), 2151-2158. https://doi.org/10.1007/s00296-022-05157-6

@article{13a9a7d1cc024ebc8772d15d6fba39d2,

title = "COVAD survey 2 long-term outcomes: unmet need and protocol",

abstract = "Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.",

keywords = "Antiviral Agents, COVID-19/prevention \& control, COVID-19 Vaccines/adverse effects, Humans, Pandemics/prevention \& control, Vaccination",

author = "Fazal, \{Zoha Zahid\} and Parikshit Sen and Mrudula Joshi and Naveen Ravichandran and Lilleker, \{James B\} and Vishwesh Agarwal and Sinan Kardes and Minchul Kim and Jessica Day and Ashima Makol and Marcin Milchert and Tamer Gheita and Babur Salim and Tsvetelina Velikova and Gracia-Ramos, \{Abraham Edgar\} and Ioannis Parodis and Elena Nikiphorou and Tan, \{Ai Lyn\} and Tulika Chatterjee and Lorenzo Cavagna and Saavedra, \{Miguel A\} and Shinjo, \{Samuel Katsuyuki\} and Nelly Ziade and Albert Selva-O'Callaghan and Arvind Nune and Johannes Knitza and Masataka Kuwana and Guti{\'e}rrez, \{Carlos-Enrique Toro\} and Caballero-Uribe, \{Carlo Vinicio\} and Dzifa Dey and Pauling, \{John D\} and \{COVAD Study Group\} and et al",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = dec,

day = "1",

doi = "10.1007/s00296-022-05157-6",

language = "English",

volume = "42",

pages = "2151--2158",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

Fazal, ZZ, Sen, P, Joshi, M, Ravichandran, N, Lilleker, JB, Agarwal, V, Kardes, S, Kim, M, Day, J, Makol, A, Milchert, M, Gheita, T, Salim, B, Velikova, T, Gracia-Ramos, AE, Parodis, I, Nikiphorou, E, Tan, AL, Chatterjee, T, Cavagna, L, Saavedra, MA, Shinjo, SK, Ziade, N, Selva-O'Callaghan, A, Nune, A, Knitza, J, Kuwana, M, Gutiérrez, C-ET, Caballero-Uribe, CV, Dey, D, Pauling, JD, COVAD Study Group & al , E 2022, 'COVAD survey 2 long-term outcomes: unmet need and protocol', Rheumatology International, vol. 42, no. 12, pp. 2151-2158. https://doi.org/10.1007/s00296-022-05157-6

TY - JOUR

T1 - COVAD survey 2 long-term outcomes

T2 - unmet need and protocol

AU - Fazal, Zoha Zahid

AU - Sen, Parikshit

AU - Joshi, Mrudula

AU - Ravichandran, Naveen

AU - Lilleker, James B

AU - Agarwal, Vishwesh

AU - Kardes, Sinan

AU - Kim, Minchul

AU - Day, Jessica

AU - Makol, Ashima

AU - Milchert, Marcin

AU - Gheita, Tamer

AU - Salim, Babur

AU - Velikova, Tsvetelina

AU - Gracia-Ramos, Abraham Edgar

AU - Parodis, Ioannis

AU - Nikiphorou, Elena

AU - Tan, Ai Lyn

AU - Chatterjee, Tulika

AU - Cavagna, Lorenzo

AU - Saavedra, Miguel A

AU - Shinjo, Samuel Katsuyuki

AU - Ziade, Nelly

AU - Selva-O'Callaghan, Albert

AU - Nune, Arvind

AU - Knitza, Johannes

AU - Kuwana, Masataka

AU - Gutiérrez, Carlos-Enrique Toro

AU - Caballero-Uribe, Carlo Vinicio

AU - Dey, Dzifa

AU - Pauling, John D

AU - COVAD Study Group

AU - al , et

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.

AB - Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.

KW - Antiviral Agents

KW - COVID-19/prevention & control

KW - COVID-19 Vaccines/adverse effects

KW - Humans

KW - Pandemics/prevention & control

KW - Vaccination

U2 - 10.1007/s00296-022-05157-6

DO - 10.1007/s00296-022-05157-6

M3 - Article (Academic Journal)

C2 - 35964271

SN - 0172-8172

VL - 42

SP - 2151

EP - 2158

JO - Rheumatology International

JF - Rheumatology International

IS - 12

ER -

COVAD survey 2 long-term outcomes: unmet need and protocol

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Handle.net

Fingerprint

Cite this